Local Institution

Rochester, Minnesota 55905-0001

0 studies enrolling now · 8 studies all time

What they study most

Bladder Cancer, Bladder Tumor, Chronic Myeloid Leukemia, Coronary Artery Disease, Giant Cell Arteritis, HIV Infections, Heart Disease, Leukemia, Metastasis, Muscle-Invasive Bladder Cancer, Non-small Cell Lung Cancer, Philadelphia-Positive Myeloid Leukemia

Studies at this site

• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer — Completed
• A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease — Completed
• A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) — Withdrawn before enrolling
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
• Atazanavir for HIV Infected Individuals: An Early Access Program — NO_LONGER_AVAILABLE
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early